- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01736124
Computerized Cognitive Training for Diabetic Elderly Veterans (CCT_DEV)
Computerized Cognitive Training to Improve Cognition in Diabetic Elderly Veterans
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Project Background: Diabetes mellitus (DM) has consistently been associated with increased risk for cognitive decline, mild cognitive impairment, and dementia in the elderly. Even minor cognitive impairments in nondemented individuals dramatically affect disease self-management. This, in turn, is associated with poor glycemic and blood pressure control in diabetes, which by themselves increase the risk of dementia, provoking a reinforcing cycle of disease. Thus, it is imperative to find interventions to delay or prevent cognitive compromise in diabetic patients, that can be relatively easily and rapidly implemented, and that are not cost prohibitive. This is especially true in the VA, in view of the high incidence of both diabetes and dementia in the growing population of elderly Veterans.
Epidemiologic evidence suggests modifiable life-style factors, including cognitive activity, may prevent or delay the onset of cognitive decline. Computerized cognitive training (CCT) is an intervention that has shown promising results in the improvement of cognitive functioning, more consistently in non-demented elderly, with additional benefits from booster training sessions. To date, studies of CCT have typically only examined cognitive outcomes, and only shortly after the intervention. The proposed CCT program, Personal Coach from Cognifit, is designed to improve cognition of elderly persons by targeting their weak cognitive functions, using a personally tailored training plan. The proposed study will provide the first evaluation of the effects of CCT on DM self-management behavior and clinical outcomes, in addition to cognition.
Project Objectives: Aim 1A: To determine whether the CCT, relative to the active control games program, improves cognition (memory and executive functions/attention), DM-related behavior (DM self-management and medication adherence), and clinical outcomes (glycemic and blood pressure control), 6 and 12 months after the intervention. Aim 1B: To demonstrate efficacy by improvement in behavioral outcomes (DM self-management and medication adherence) 6 months after the intervention. Aim 2: To document the effects of CCT on the successive changes in memory and executive functions/attention, DM self-management and medication adherence, and glycemic and blood pressure control. Aim 3: To explore the impact of demographic (age, education, ethnicity, site) and health (ADL/IADL, health literacy, depression, dementia family history, lifestyle factors) characteristics, on the intervention effects.
Project Methods: Non-demented DM elderly from the James J. Peters (Bronx, NY) and Ann Arbor (MI) VAMCs will be randomized to CCT or games intervention and perform the respective program 3 days per week (every other day), for 20 minutes, for 24 total sessions. Four months after the intervention, subjects will receive a 1-week booster training. Subjects will be assessed at baseline; and immediately, 6 months, and 12 months after the intervention. At each time point, assessments will be cognitive function, DM self-management, and blood pressure; blood will be drawn for HbA1c measurement. VA records will be used to monitor medication adherence. Longitudinal mixed model analyses will assess the effects of the intervention on change in outcomes over time. Path analyses will evaluate the inter-relationships among changes in cognition, DM self-management, and clinical outcomes for each intervention at 6 and 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10468-3904
- James J. Peters VA Medical Center, Bronx, NY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 55 years old or above
- A diagnosis of type 2 diabetes
- Access to computer and internet
- Has an informant
- Self-management score 18 or below
Exclusion Criteria:
- Dementia or prescribed AD medications
- Major medical, psychiatric, or neurological conditions that affect cognitive performance
- Severe impairment of vision, hearing or fine motor control necessary for computer operation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Computerized Cognitive Training (CCT)
Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
|
A variety of computer games tailored to address their personal cognitive deficits.
|
Active Comparator: Active control
Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
|
A variety of computer games that are engaging but not designed to enhance cognitive skills
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diabetes Self-management
Time Frame: 6 months after the intervention
|
The data below represent values of the Diabetes Self-Management Questionnaire (DSMQ) scores at 6 months post-intervention, the primary outcome.
DSMQ scores range from 0 to 20, with higher scores indicating better self-management, the same as baseline.
|
6 months after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Adherence
Time Frame: 12 months post-intervention
|
Medication adherence was assessed by the Continuous Multiple interval measure of Gaps in therapy (CMG), using diabetes medication refill data from the CPRS for the full year post-intervention.
To calculate CMG percentage, the total number of days without medication refills when due - refill gap-days - was divided by 365, the days in a year.
Multiplying this fraction by 100 provides the CMG percentage, where a higher percentage indicates worse medication adherence.
The data below represent the CMG percentage at 12 months post-intervention.
|
12 months post-intervention
|
Memory
Time Frame: 6 month after the intervention
|
As with baseline memory score, the outcome score was the mean of Word List Memory and Logical Memory (Story A) tests, each providing three scores: immediate recall, delayed recall, and recognition tasks after conversion to a common unit of measurement.
However, to standardize these outcome tasks, the statistics from which the baseline z-scores were calculated (mean_baseline and SD_baseline from the full sample before randomization) were used, rather than the means of the given outcome period: standardized score = (outcome task score - mean_baseline) / SD_baseline.
Thus, while baseline task scores were conventional z-scores, the six-month post-intervention standardized scores were not, in order to best inform the outcome measure and better facilitate comparison with baseline.
The data below represent outcome values at 6 months.
Like the baseline measure, this measure does not have a theoretical minimum or maximum, and higher scores indicate better performance.
|
6 month after the intervention
|
Executive Function/Attention
Time Frame: 6 months after the intervention
|
As with baseline attention/executive function score, the outcome score was the mean of the Target Cancellation (TMX, Diamond), Trail Making (A, B; reversed), Digit Symbol Substitution, and, Digit Span (Forward, Backward) tasks after conversion to a common unit of measurement.
However, to standardize these outcome tasks, the statistics from which the baseline z-scores were calculated (mean_baseline and SD_baseline from the full sample before randomization) were used, rather than the means of the given outcome period: standardized score = (outcome task score - mean_baseline) / SD_baseline.
Thus, while baseline task scores were conventional z-scores, the six-month post-intervention standardized scores were not, in order to best inform the outcome measure and better facilitate comparison with baseline.
The data below represent outcome values at 6 months.
Like the baseline measure, this measure does not have a theoretical minimum or maximum, and higher scores indicate better performance.
|
6 months after the intervention
|
Hemoglobin A1c
Time Frame: 6 months after the intervention
|
A measure of glycemic control derived from blood sample.
The data below represent outcome values at 6 months.
Higher values represent poorer control of glycation.
|
6 months after the intervention
|
Systolic Blood Pressure
Time Frame: 6 months after the intervention
|
A measure of the extent of pressure that blood is exerting against an individual's artery walls when the heart beats, assessed using a blood pressure cuff.
Higher values indicate worse outcome.
The data below represent outcome values at 6 months.
|
6 months after the intervention
|
Diastolic Blood Pressure
Time Frame: assessed 6 months after intervention
|
A measure of the extent of pressure of the blood in the arteries when the heart is filling, assessed using a blood pressure cuff.
Higher values indicate worse outcome.
The data below represent outcome values at 6 months.
|
assessed 6 months after intervention
|
Prospective Memory
Time Frame: 6 months after the intervention
|
The "Appointments - Delayed Recall" subtest of the Rivermead Behavioral Memory Test - Third Edition (RBMT - 3) is a test of prospective memory - remembering to do something in the future.
The examinee was instructed to ask two questions when an alarm rings 25 minutes later.
For each question, a score of 2 was given when a participant responded without requiring a prompt, 1 point when a prompt was needed and elicited a correct response, and 0 when there was no appropriate response despite prompting.
Scores were summed and the total score ranges from 0 to 4. Higher scores indicate better performance.
The data below represent outcome values at 6 months.
|
6 months after the intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeremy Silverman, PhD, James J. Peters Veterans Affairs Medical Center
Publications and helpful links
General Publications
- Karran M, Guerrero-Berroa E, Schmeidler J, Lee PG, Alexander N, Nabozny M, West RK, Beeri MS, Sano M, Silverman JM. Recruitment of Older Veterans with Diabetes Risk for Alzheimer's Disease for a Randomized Clinical Trial of Computerized Cognitive Training. J Alzheimers Dis. 2019;69(2):401-411. doi: 10.3233/JAD-180952.
- Silverman JM, Schmeidler J, Lee PG, Alexander NB, Beeri MS, Guerrero-Berroa E, West RK, Sano M, Nabozny M, Rodriguez Alvarez C. Associations of hemoglobin A1c with cognition reduced for long diabetes duration. Alzheimers Dement (N Y). 2019 Dec 11;5:926-932. doi: 10.1016/j.trci.2019.11.009. eCollection 2019.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIR 11-285
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on computerized cognitive training
-
Hadassah Medical OrganizationCompletedAttention Deficit Hyperactivity DisorderIsrael
-
Michigan State UniversityUniversity of Michigan; Global Health Uganda LTDCompleted
-
Rick GuliziaCompletedPosttraumatic Stress Disorder
-
University of BernRecruitingDementia | Alzheimer Disease | Mild Cognitive ImpairmentSwitzerland
-
University of Wisconsin, MilwaukeeRecruitingObsessive-Compulsive Disorder | Skin-Picking | TricholemmomaUnited States
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
University of MinnesotaNational Institute of Mental Health (NIMH)RecruitingPsychotic Disorders | Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizoaffective Disorder | Psychosis | Schizo Affective Disorder | Schizophreniform Disorders | Psychoses, Affective | Psychotic Mood Disorders | Psychosis Nos/OtherUnited States
-
Universidade Federal do Rio de JaneiroUnknown
-
University of FloridaNational Institute on Aging (NIA)RecruitingAmnestic Mild Cognitive ImpairmentUnited States
-
University of South FloridaNational Institute on Aging (NIA); University of Florida; University of California... and other collaboratorsRecruitingDementia | Mild Cognitive Impairment | Age-related Cognitive DeclineUnited States